Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin for Overactive Bladder After TURP or PVP
NCT01747577Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2012
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Solifenacin group with Placebo group (2 arms). Primary endpoint: Mean change from baseline in the number of urgency episodes per 24 hrs at 2 weeks. Started Dec 2012; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01747577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01747577.